A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

Phase 3

SolriamfetolA Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

Sponsor:

Axsome Therapeutics, Inc.

Code:

NCT05972044

Conditions

ADHD

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Solriamfetol 150 mg

Solriamfetol 300 mg

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by Axsome Therapeutics, Inc. on 2025-04-03.